HanchorBio Unveils First-in-Human Results for HCB101 in NHL
HanchorBio Inc. has recently shared groundbreaking early Phase 1 monotherapy data that indicates robust safety and clinical activity for HCB101, a 3.5th generation SIRP?-Fc fusion protein targeting relapsed and refractory non-Hodgkin lymphoma (NHL). This significant progress was presented at the prestigious annual meeting of the American Society of Hematology (ASH).
What is HCB101?
HCB101 is an innovative therapy developed by HanchorBio, specifically designed to modify the immune response in cancer patients. Utilizing a novel approach, this treatment has been optimized to minimize common side effects such as anemia and thrombocytopenia while retaining strong immune activation capabilities. The company has strategically advanced this product to potentially provide effective solutions for patients facing NHL.
Efficiency and Safety Profile
During the initial study phase, thirteen participants diagnosed with R/R NHL received HCB101 at varying doses ranging from 5.12 to 24.0 mg/kg. Remarkably, no dose-limiting toxicities were identified, highlighting an impressive safety profile. Adverse events that occurred were reported as Grade 1-2, confirming the cytopenia-sparing nature that HanchorBio emphasized.
Clinical Progress and Insights
The abstract presented by HanchorBio at ASH showcases a focused analysis from their multinational Phase 1 study of HCB101. A notable response was documented in one patient with marginal zone B-cell lymphoma, wherein significant tumor reduction was observed, showcasing the potential effectiveness of HCB101 as a treatment option in previously difficult cases.
Significant Findings from the Study
Among the positive outcomes detailed in the study findings, the investment in HCB101’s development has illustrated a high level of CD47 receptor occupancy. At specific dosage points, occupancy rates hit between 75-90%, indicating a broad pharmacological window. Coupled with the absence of major safety concerns, these findings provide a strong basis for HCB101's continued development.
Industry Impact and Future Directions
The ASH meeting serves as a vital platform for cutting-edge developments in hematology, making the presentation of HCB101 data a notable achievement for HanchorBio. This showcases the company's dedication to pushing boundaries in cancer treatment through innovative biologics development as they look forward to further engagements in the hematology field.
HanchorBio's President and Chief Executive Officer, Dr. Alvin Luk, emphasized the importance of this data, noting the transition from molecular design to real-world application as a testament to HCB101's innovative design. The findings have set a solid groundwork for further clinical exploration of HCB101 in various malignancies and combination strategies, marking a pivotal moment in HanchorBio's mission to transform cancer therapy.
About HanchorBio
HanchorBio, with its base in Taipei, Shanghai, and the San Francisco Bay Area, is dedicated to innovating immuno-oncology therapies for addressing complicated medical challenges in cancer treatment. Their proprietary Fc-based designer biologics (FBDB™) platform signifies a groundbreaking approach to developing versatile biologics that activate both innate and adaptive immunity, facilitating significant advancements in the battle against cancer.
Frequently Asked Questions
What is the main focus of HanchorBio's research?
HanchorBio focuses on next-generation immunotherapies for oncology and autoimmune diseases, primarily through products like HCB101.
How does HCB101 differ from traditional therapies?
HCB101 aims to offer a safer profile with fewer side effects, specifically avoiding anemia and thrombocytopenia, common issues with traditional anti-CD47 therapies.
What were the results of the recent Phase 1 study?
The recent study highlighted no dose-limiting toxicities, a cytopenia-sparing profile, and significant evidence of clinical activity in relapsed/refractory non-Hodgkin lymphoma patients.
Who presented the findings at ASH?
The findings were presented by Dr. Alvin Luk, who is the President and Chief Medical Officer of HanchorBio.
What is HCB101 developed from?
HCB101 is developed using a proprietary FBDB™ platform that focuses on enhancing immune responses while minimizing adverse effects.
